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1 |  INTRODUCTION
Malignant peripheral nerve sheath tumors are aggressive 
sarcomas that account for approximately 5% of all soft tis-
sue sarcomas. Approximately, 50% of these tumors occur 
in patients with the Neurofibromatosis Type 1 (NF1) can-
cer predisposition syndrome, while the other half occur 
sporadically or as a secondary complication of radiation 
therapy.1,2 In the setting of NF1, MPNSTs arise from 
malignant transformation of a benign precursor lesion, a 
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Abstract
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive 
sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 
(NF1) cancer predisposition syndrome. Despite aggressive multimodality therapy, 
outcomes are dismal and most patients die within 5 years of diagnosis. Prior genomic 
studies in our laboratory identified tyrosine kinase 2 (TYK2) as a frequently mutated 
gene in MPNST. Herein, we explored the function of TYK2 in MPNST pathogenesis.
Methods: Immunohistochemistry was utilized to examine expression of TYK2 in 
MPNSTs and other sarcomas. To establish a role for TYK2 in MPNST pathogenesis, 
murine and human TYK2 knockdown and knockout cells were established using 
shRNA and CRISPR/Cas9 systems, respectively.
Results: We have demonstrated that TYK2 was highly expressed in the majority of 
human MPNSTs examined. Additionally, we demonstrated that knockdown of Tyk2/
TYK2 in murine and human MPNST cells significantly increased cell death in vitro. 
These effects were accompanied by a decrease in the levels of activated Stats and 
Bcl‐2 as well as an increase in the levels of Cleaved Caspase‐3. In addition, Tyk2‐KD 
cells demonstrated impaired growth in subcutaneous and metastasis models in vivo.
Conclusion: Taken together, these data illustrate the importance of TYK2 in MPNST 
pathogenesis and suggest that the TYK2 pathway may be a potential therapeutic tar-
get for these deadly cancers.
K E Y W O R D S
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plexiform neurofibroma.3 Initial treatment for MPNSTs 
typically involves surgery and radiation with or without 
chemotherapy.4 However, despite aggressive therapy, the 
recurrence rate is high and the vast majority of people 
with these cancers will die within 5 years of diagnosis.5-8 
Treatment for metastatic disease is limited to cytotoxic 
chemotherapy and clinical trials evaluating experimen-
tal therapies. As such, there is a pressing need to identify 
novel therapeutic targets.
Prior work from our laboratory identified TYK2 as a 
gene mutated and frequently overexpressed in a subset of 
MPNSTs.9 Tyrosine kinase 2 (TYK2) is a member of the 
Janus kinase (JAK family),10 which includes three other mem-
bers, JAK1‐3. These proteins are non‐receptor tyrosine ki-
nases that are activated by auto or trans‐phosphorylation after 
a cytokine binds to its respective receptor.11,12 Subsequently, 
JAKs activate signal transducers and activators of transcrip-
tion proteins (STATs) which form homo‐/hetero dimers and 
then following phosphorylation, translocate into the nucleus 
to induce the transcription of target genes.13,14 STAT protein 
family members have been shown to regulate oncogenic sig-
naling in many tumor types often through the expression of 
downstream target genes such as cyclin D, Bcl‐2, and Bcl‐x, 
which regulate cell proliferation15,16 and apoptosis17 of tumor 
cells. Herein, we have explored the role of TYK2 in MPNST 
pathogenesis. First, we have shown that TYK2 is expressed 
in over 60% of human MPNSTs. Second, knockdown of the 
gene in murine and human MPNST cells led to decreased 
phosphorylation of STAT proteins, decreased levels of Bcl2, 
and increased cell death in vitro. Finally, we showed that 
knockdown of the gene led to decreased tumor burden in 
a primary and metastatic xenograft model. Taken together, 
these data suggest that TYK2 is a potential therapeutic target 
for MPNSTs.
2 |  METHODS
2.1 | Cell culture
Murine MPNST tumor lines expressing GFP‐Luciferase estab-
lished previously in our laboratory from C57BL6/J Nf1±;Trp53± 
(NPcis),18 and human MPNST 724 cell lines obtained from 
Jonathan Fletcher (Dana Farber Cancer Institute) were used for 
all in vitro and in vivo experiments. Cells were cultured in high‐
glucose DMEM (Gibco Life Technologies, Grand Island, NY, 
USA), with 10% FBS (Gibco Life Technologies, Grand Island, 
NY, USA) and penicillin‐streptomycin (200 µg/mL).
2.2 | Lentiviruses
Lentiviral Tyk2 shRNA (TRCN0000236001, TRCN000023 
6003, TRC0000361657, MilliporeSigma, St. Louis, MO) or con-
trol LacZ shRNA (McDonnell Genome Institute, Washington 
University) containing pLKO.1‐puro plasmids were utilized for 
in vitro and in vivo murine MPNST cell experiments. Each con-
struct was co‐transfected into HEK293T cells with the packag-
ing plasmid pMDLg, pCMVg, and pREV using Mirus reagent 
(MilliporeSigma) to generate virus. After a 24‐hour infection, 
JW23.3 murine MPNST cells were subjected to selection media 
containing 2 µg/mL puromycin.
Three lentiviral shTyk2 constructs were screened and used 
in vitro. The two constructs with the best knockdown were 
chosen for in vivo experiments.
2.3 | CRISPR‐Cas9‐mediated TYK2 
knockout in MPNST 724 cells
We designed the sgRNA using the websitehttp://tools.ge-
nome-engin eering.org.19
gRNA #1‐1 CACCG GGCCCCACCTGGTAGGCATT AAAC AATGCCTACCAGGTGGGGCC C
gRNA #1‐2 CACCG GCCATGGACAAGTGGGGGTT AAAC AACCCCCACTTGTCCATGGC C
gRNA #2‐1 CACCG GCCCCACCTGGTAGGCATTC AAAC GAATGCCTACCAGGTGGGGC C
gRNA #2‐2 CACCG GCCATGGACAAGTGGGGGTT AAAC AACCCCCACTTGTCCATGGC C
gRNA #3‐1 CACCG GGAGACCTGGCTCATGAGGC AAAC GCCTCATGAGCCAGGTCTCC C
gRNA #3‐2 CACCG GTGCATGGCGTCTGTGTGCG AAAC CGCACACAGACGCCATGCAC C
gRNA #4‐1 CACCG ACTCAGCTTGATGAAGGGGC AAAC GCCCCTTCATCAAGCTGAGT C
gRNA #4‐2 CACCG GGGCCTGGGCGCCCTCTCCA AAAC TGGAGAGGGCGCCCAGGCCC C
gRNA #5‐1 CACCG CACCACCATCTTCCAAGCCA AAAC TGGCTTGGAAGATGGTGGTG C
gRNA #5‐2 CACCG GGCCAGCGCCCTCAGCTACC AAAC GGTAGCTGAGGGCGCTGGCC C
gRNA #6‐1 CACCG GCACACGCTGAACACTGAAG AAAC CTTCAGTGTTCAGCGTGTGC C
gRNA #6‐2 CACCG GCAGCCCTGCCTGGGAGGAC AAAC GTCCTCCCAGGCAGGGCTGC C
We constructed the pSpCas9n(BB)‐2A‐Puro (PX462)‐
TYK2 plasmid by inserting the sgRNA into the plasmid. 
MPNST 724 cells (1  ×  105  cell/well) were transfected 
(Lipofectamine, Invitrogen, USA) with the paired plasmid 
with or without sgRNA. Cells were then puromycin se-
lected for 72  hours. Two clones with the best knockout as 
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demonstrated by western blot were chosen for analysis (#5 
2 and #6 4 lines). One control clone was selected for further 
study as well (Control 8).
2.4 | Western blot analysis
Cells were lysed in 1× Cell Lysis Buffer (Cell Signaling 
Technology, Danvers, MA). Protein content was quantified 
using the BCA kit (ThermoFisher Scientific, USA). Primary 
antibody incubations were performed at 4°C overnight 
(phospho‐STAT1(SC‐8394), phospho‐STAT3(SC‐8001‐R), 
STAT1(SC‐464), STAT3(SC‐23151), and Bcl2(SC‐7382) at 
1:500, Santa Cruz Biotechnology, Dallas, Texas, USA; TYK2 
(720124), GAPDH(AM4300), ThermoFisher Scientific, USA, 
Caspase3(9662) and Cleaved Caspase‐3(9661) at 1:1000; 
Cell  Signaling  Technology) diluted in 5% BSA TBS‐T. 
Secondary antibodies used included goat anti‐rabbit or goat 
anti‐mouse (Cell Signaling Technology) peroxidase‐conju-
gated antibodies (at 1:10000 dilution in 5% BSA TBS‐T). The 
protein levels were calculated by measuring the peak densito-
metric area (Image‐J). Each western blot analysis was repeated 
in triplicate. Phosphorylated and un‐phosphorylated proteins 
were run and detected on the same blot after stripping.
2.5 | mRNA quantification
RNA was isolated using the TRIzol method (ThermoFisher 
Scientific, USA), then quantitated with the Nanodrop 2000 
(ThermoFisher Scientific, USA). Reverse transcription re-
actions were performed with Superscript III (ThermoFisher 
Scientific, USA) according to the manufacturer's protocols. 
Quantitative PCR was performed in a CFX96 Touch™ Real‐
Time PCR  Detection System (Bio‐Rad, USA) using the 
SYBR® Green based qPCR kit (MilliporeSigma, St. Louis 
MO, USA). Primers used included:
murine Tyk2 
Forward 5′‐GTGACTCTAACCAG 
AGTCCCCATA‐3′,
  Reverse 5′‐CTGACCTTGGTACTT 
CTCCTGTG‐3′,
human TYK2 Forward 5′‐GACAGTCCATGAGA 
AGTACCAAGG‐3′,
  Reverse 5′‐CTCTAGACAGGAGT 
AAGGCACAC‐3′,
murine Gapdh Forward 5′‐TCAACAGCAACTCC 
CACTCTTCCA‐3′,
  Reverse 5′‐ACCCTGTTGCTGTA 
GCCGTATTCA‐3′,
human GAPDH Forward 5′‐TGTTGCCATCAATG 
ACCCCTT‐3′,
  Reverse 5′‐CTCCACGACGTACT 
CAGCG‐3′.
These were synthesized by IDT (Integrated DNA 
Technologies, San Diego, CA). Relative gene expression 
was determined using CFX ManagerTM Software version 
3.1 (Bio‐Rad, USA) by CFX96 TouchTM and CFX96 Touch 
Deep wellTM Real‐Time PCR Detection Systems; ms‐Gapdh 
and hu‐GAPDH gene were used as reference genes for ex-
pression analysis.
2.6 | Cell proliferation and cell death assays
Control shLacZ JW23.3, shTyk2 #1 JW23.3, shTyk2 #2 
JW23.3, and shTyk2 #3 JW23.3, were cultured in standard con-
ditions with 2 µg/mL puromycin, then plated at 5000 cells/well 
in 96‐well plates. For proliferation assays, cells were plated 
in phenol‐red free DMEM with 10% FBS. Cells were imaged 
every hour for 48 hours using the IncuCyte FLR imaging sys-
tem (Essen Bioscience, Ann Arbor, MI, USA) and analyzed 
for quantitation using IncuCyte ZOOM Analysis Software 
(Essen Bioscience, Ann Arbor, MI) Phase images were used 
to determine percent confluence and subsequent wells were 
normalized to initial confluence. For cell death assays, 50nM 
TOTOTM‐3 iodide (ThermoFisher Scientific, USA) was added 
to the phenol‐red free media with reduced serum as a stress 
(5% FBS). Cells were imaged every hour for 48 hours using the 
IncuCyte FLR imaging system (Essen Bioscience, Ann Arbor, 
MI). For quantification of cell death, the TOTOTM‐3 iodide flu-
orescence was normalized to the confluency factor calculated 
from the phase of each respective well.
2.7 | Tumor cell injections
For the subcutaneous model, a total of 2  ×  106 shLacZ 
JW23.3, shTyk2 #2 JW23.3, or shTyk2 #3 JW23.3, tumor 
cells were injected into the dorsal surface of 5‐week‐old 
C57BL/6 ALBINO mice (Charles River Labs). Tumor vol-
umes were measured weekly for the first 2 weeks and then 
every other day for the final week. For the left ventricular 
metastatic model, a total of 1 × 105 shLacZ JW23.3, shTyk2 
#2 JW23.3, or shTyk2 #3 JW23.3, tumor cells were injected 
into the left ventricle of 5‐week‐old C57BL/6 ALBINO mice 
(Charles River Labs). These mice were followed by biolumi-
nescence imaging (BLI) with weekly weights. (n = 5 mice 
per group). These experiments were all repeated indepen-
dently and similar results were obtained. The Institutional 
Animal Care and Use Committee of Washington University 
has reviewed and approved our protocol for experiments uti-
lizing animals. All animals are treated in compliance with 
IACUC policies.
2.8 | Bioluminescence imaging (BLI)
BLI was performed on an IVIS 50 or IVIS Lumina 
(PerkinElmer; Living Image 4.3 or 3.2, 1  sec–5  minutes 
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exposures, binning 2, 4, or 8; FOV 12  cm, f/stop1, open 
filter). In vivo bioluminescence was measured weekly post 
tumor cell injection following i.p. injection of D‐luciferin 
(150  mg/kg; Gold Biotechnology, Inc). Total photon flux 
(photons/second) was measured from fixed regions of inter-
est over the entire mouse using Living Image 2.6.
2.9 | Statistical analysis for in vivo and 
in vitro studies
In vivo tumor growth data GraphPad Prism Version 6 was 
used to perform a two‐way ANOVA analysis to determine 
statistical significance. Kaplan‐Meier analysis was used to 
determine statistical significance for overall survival. For all 
other in vivo and in vitro other experiments GraphPad Prism 
Version 6 was used to perform two‐tailed t‐tests to determine 
statistical significance.
2.10 | Human tissue acquisition
Unstained slides were obtained from cases from individu-
als diagnosed with MPNSTs and treated at Washington 
University/St. Louis Children's Hospital NF Clinical Program 
(St. Louis, MO) under active Human Studies Protocols ap-
proved by the Institutional Review Boards in accordance 
with the 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards. All human tumor samples 
were collected under an IRB approved protocol 201203042 
and patients were appropriately consented.
2.11 | Immunohistochemistry
Immunohistochemical staining was performed using a rabbit 
polyclonal antibody to TYK2 antibody at 1:1000 (ab39550; 
Abcam, Cambridge, Mass), Cleaved Caspase‐3 at 1:500 
(Cell Signaling Technology) with citrate antigen retrieval on 
whole tissue sections from the most representative areas of the 
tumor, as well as from normal peripheral nerve. Breast carci-
noma was used as a positive control for TYK2 staining. Images 
were acquired with the 40X objective using the Olympus DP70 
Microscope Digital Camera and DP70‐BSW software. For 
TYK2 staining, tumors with strong immunostaining in >80% of 
the cells were scored as positive. Tumors with strong to moder-
ate staining in 25%‐80% of cells were called moderate. Tumors 
with weak staining in <25% of cells or no immunostaining were 
deemed negative. No tumors called negative demonstrated any 
areas of moderate to strong staining.
2.12 | Clinical data statistical analysis
Two‐way ANOVA analyses were performed to estimate the 
difference of tumor growth rates over time between Tyk2 
knockdown and control groups. The t‐tests were used to com-
pare continuous variables between groups for In vitro experi-
ments. The association between TYK2 protein expression and 
H3K27 me status was assessed by Fisher's Exact Test. Patient 
characteristics were compared between TYK2 normal and ab-
errant patients using χ2 test or Fisher exact test for categorical 
variables while non‐parametric Wilcoxon rank sum test was 
used for continuous variables. Kaplan‐Meier survival curves 
were generated for overall survival by TYK2 protein expres-
sion groups in MPNST. Patients were censored by date of death 
(Social Security Death Index, expiration note in chart or obitu-
ary) or date of last follow‐up. Overall survival is defined as date 
from diagnosis to date of death by any cause. The survival dif-
ference between groups was compared using the log‐rank test. 
Raw hazard ratios (HR) and 95% CI were estimated from uni-
variate Cox model. All tests were two‐sided and P‐value ≤0.05 
is considered statistically significant. Statistical analyses were 
performed with GraphPad Prism Version 6 and SAS (version 
9.4; SAS Institute, Cary, NC).
3 |  RESULTS
3.1 | TYK2 is expressed in the majority of 
MPNSTs
We first set out to examine TYK2 expression in a set 
of MPNSTs and other sarcomas in order to determine if 
TYK2 expression could serve as a diagnostic biomarker 
for MPNSTs. We performed IHC on full tissue sections 
from 30 MPNSTs, 18 plexiform neurofibromas, 5 fibro-
sarcomas, 9 synovial sarcomas, 13 undifferentiated pleo-
morphic sarcomas, and 13 leiomyosarcomas. As can be 
seen in Figure 1, strong staining was observed in 63% of 
MPNSTs as well as 38%‐89% of other sarcomas, depend-
ing on the histologic subtype, but only 11% of benign 
plexiform neurofibromas. Table 1 depicts the clinical data 
associated with the MPNSTs in this study. A Fischer Exact 
Test was performed for each clinical parameter to see if 
there was any correlation between TYK2 expression. In 
this small sample size, no statistically significant correla-
tion was observed. The polycomb repressive complex 2 
(PRC2)/polycomb repressive complex 2 subunit (SUZ12) 
has recently been shown to play an important role in 
MPNST pathogenesis.20,21 Given that PRC2 loss occurs 
in 60%‐70% of MPNSTs and affects transcriptional regu-
lation, we sought to determine whether there was a cor-
relation between PRC2 loss and TYK2 expression, which 
could suggest a link between these events. As a surrogate 
for PRC2/SUZ12 loss, we performed immunohistochem-
istry to examine H3K27 me3, a known downstream target 
of SUZ12. However, there was no correlation between 
these events in this cohort as determined by a Fischer 
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Exact Test. Nonetheless, these data do suggest that TYK2 
protein overexpression is prevalent in malignant tumors 
and could be targetable in MPNSTs as well as other sar-
comas. Given that TYK2 is expressed at high levels in the 
majority of MPNSTs, we went on to look at the functional 
role in this subset of sarcomas.
3.2 | Loss of TYK2 leads to increased cell 
death in vitro
To explore the function of Tyk2 in vitro, we utilized JW23.3 
Nf1/Tp53‐ mutant NPcis murine MPNST cells engineered 
to express firefly luciferase. Following Tyk2 shRNA‐me-
diated knockdown, there was reduced expression of Tyk2 
by western blot compared to control shLacZ virus infection 
(Figure 2A), as well as decreased expression at an mRNA 
level (Figure 2B). Reduced Tyk2 expression was associ-
ated with decreased cell confluence over time (Figure 2C, 
Supplemental Figure S1A) as well as increased cell death 
as assessed by increased incorporation of TOTOTM‐3 io-
dide, a fluorescent dye binding to cell‐free DNA (Figure 
2D, Supplemental Figure S1B) compared to control cells. 
To ensure that these data were not an artifact of a single 
cell line, we next used the CRSIPR/Cas9 system to knockout 
TYK2 in human MPNST 724 cells and demonstrated similar 
findings (Figure 2E‐H, Supplemental Figure S1C and D). To 
explore potential downstream targets by which TYK2 could 
be exerting its effects on cell death in MPNSTs, we first ex-
amined phosphorylation status of several downstream STAT 
proteins, as these are known targets for Tyk2.16,17 As can 
be seen in Figure 3, upon knockdown of Tyk2 (Figure 3A 
and B) there was a significant reduction in levels of phos-
pho‐STAT1 and phospho‐STAT3 in both murine and human 
cell lines (Figure 3C‐F). Additionally, there was a decrease 
in levels of the anti‐apoptotic protein, Bcl‐2 (Figure 3G 
and H), another protein shown to be regulated by TYK2 in 
F I G U R E  1  Tyrosine kinase 2 (TYK2) 
protein expression in malignant peripheral 
nerve sheath tumors (MPNSTs) and other 
sarcomas. TYK2 immunoreactivity was 
observed NF1‐associated and sporadic 
MPNSTs as well as other sarcomas. 
(A) Representative images of positive 
and negative staining for Plexiform 
Neurofibromas, NF1‐associated MPNSTs, 
sporadic MPNSTs, and Undifferentiated 
Pleomorphic Sarcoma (UPS), and 
fibrosarcoma. (B) Quantification of number 
of positive and negative cases observed for 
each type of tumor
Strong/Moderate Weak/Negative
TYK2A
Plexiform Neurofibroma
MPNST
Sporadic MPNST
Fibrosarcoma
B
Tumor Type Strong/Moderate Weak/Negative
Plexiform neurofibroma 2/18 (11%) 16/18
MPNST 19/30 (63%) 11/30
Synovial sarcoma 8/9 (89%) 1/9
Fibrosarcoma 3/5 (60%) 2/5
Undierentiated pleomorphic sarcoma(UPS) 7/13 (54%) 6/13
Leiomyosarcoma 5/13 (38%) 8/13
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other models.16 This was associated with increased levels of 
Cleaved Caspase‐3 (Figure 3I and J).
3.3 | Loss of TYK2 leads to decreased 
tumor burden in vivo
We next chose shTyk2 #2 and shTyk2 #3 to use to determine 
the effects of Tyk2 knockdown in vivo using the JW23.3 
Nf1/Tp53‐mutant NPcis murine MPNST cells. These lines 
were chosen as they produced the greatest and most con-
sistent knockdown of Tyk2. In a subcutaneous model of 
tumor growth, we observed decreased tumor volume over 
time in the setting of Tyk2 knockdown (Figure 4A and B). 
Additionally, tumor sections from these mice demonstrated 
increased numbers of Cleaved Caspase‐3 positive cells 
(Figure 4C  and 4D), demonstrating that at least a subset 
of cells are going through apoptosis. Furthermore, in a left 
ventricular tumor injection model of tumor dissemination 
and metastasis, we observed decreased tumor burden over 
time in mice injected with Tyk2‐deficent cells compared to 
mice injected with control cells (Figure 4E and 4F). This 
was associated with decreased weight loss (Supplemental 
Figure S2A) and increased overall survival (Supplemental 
Figure S2B).
4 |  DISCUSSION
MPNSTs are aggressive sarcomas with limited treatment op-
tions and a dismal overall survival. As such, better therapies 
are desperately needed for these tumors. Prior work from our 
laboratory identified potential activating mutations in TYK2 
in one‐third of MPNSTs examined. TYK2, a member of the 
Janus Kinase family of proteins has been shown to play a role 
in immune surveillance and host response in the setting of 
infection, autoimmune disorders, and malignancy.22-25 More 
recent cancer genomic studies have identified activating 
mutations in TYK2 within cancer cells, implicating a cell in-
trinsic role for TYK2 in promoting cancer progression.9,25-27 
Based on these genomic studies, we have begun to explore 
the role of TYK2 in MPNST pathogenesis. The current study 
raises several important points. First, we have demonstrated 
the TYK2 is present in the majority of MPNSTs. In this co-
hort, we performed an analysis to see if there was any corre-
lation between TYK2 expression and overall survival or any 
other clinical parameter. Unfortunately, we did not see any 
statistically significant associations in this set. Future work 
is aimed obtaining a larger sample set through collaboration 
with several other NF centers. Nonetheless, the strong stain-
ing in the majority of MPNSTs suggests that TYK2 could be 
Characteristic
TYK2 positive 
(N = 18)
TYK2 Negative 
(N = 11)
Total 
(N = 29) P‐value
Sex, n (%)       0.4497
Male 10 (56) 4 (36) 14 (48)  
Female 8 (44) 7 (64) 15 (52)  
Age at diagnosis, y       0.3419
Median 39 47 42  
Range 22‐60 18‐79 18‐79  
NF Status, n (%)       0.4486
NF1 8 (44) 3 (27) 11 (38)  
Sporadic 10 (56) 8 (73) 18 (62)  
Grade, n (%)       n/a
High 18 (100) 11 (100) 29 (100)  
Low 0 (0) 0 (0) 0 (0)  
Stage at diagnosis, n (%)       1.0
IV 3 (17) 1 (9) 4 (14)  
Other 15 (83) 10 (91) 25 (86)  
Site of tumor, n (%)       0.3312
Extremity 2 (11) 5 (45) 7 (28)  
Other 15 (83) 6 (55) 21 (72)  
H3K27 Trimethylation 
staining, n (%)
      0.4328
Positive 11 (61) 4 (36) 15 (52)  
Negative 7 (39) 6 (54) 13 (45)  
T A B L E  1  Clinical characteristics of 
MPNST patient
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a therapeutic target for a large proportion of these tumors. 
While, we had initially hoped that expression of TYK2 could 
serve as a potential biomarker distinguishing MPNSTs from 
other soft tissue sarcomas, we observed high expression in 
38%‐89% of other sarcomas as well. As such, TYK2 ex-
pression is unlikely to serve as a diagnostic biomarker for 
MPNSTs, but these data do suggest that TYK2 could be a 
therapeutic target in other sarcoma subtypes as well. Future 
work is aimed at evaluating this possibility.
Second, we have demonstrated that decreased expres-
sion of TYK2 in both human and mouse MPNST cells leads 
to decreased cell survival, decreased activation of STAT1 
and 3, and decreased levels of Bcl2 in vitro. Interestingly, 
STAT3 has been previously implicated in MPNST patho-
genesis.28 Taken together, these data suggest that the TYK2 
pathway could serve as a therapeutic target in MPNSTs. 
Future work is aimed at dissecting the upstream compo-
nents in this pathway and identifying other downstream tar-
gets that could be involved in controlling TYK2‐dependent 
cell survival. Third, we demonstrate that reduced levels of 
Tyk2 leads to decreased tumor growth in subcutaneous and 
left ventricular models of tumor inoculation in a murine 
MPNST. Interestingly, while there were far more Cleaved 
Caspase‐3 positive cells in the Tyk2 knockdown tumors 
compared to control, there were still a large number of 
cells that were not Cleaved Caspase‐3 positive. Despite this 
F I G U R E  2  Loss of Tyk2/TYK2 in 
JW23.3 murine MPNST and MPNST 724 
cells leads to increased cell death. shTyk2‐
infected JW23.3 cell lines and control 
shLacZ: (A) Western blot densitometry 
analysis measuring TYK2 protein. (B) 
Relative Expression of Tyk2 mRNA 
compared to Gapdh. (C) An Incucyte cell 
proliferation assay measuring confluence 
over time. (D) An Incucyte death assay 
measuring TOTOTM-3 iodide fluorescence 
as an indicator of death over time. TYK2 
knockout MPNST 724 cells and scramble 
control: (E) Western blot densitometry 
analysis of TYK2 protein. (F) Relative 
Expression of TYK2 mRNA compared to 
GAPDH. (G) An Incucyte cell proliferation 
assay measuring confluence over time. 
(H) An Incucyte death assay measuring 
TOTOTM-3 iodide fluorescence as an 
indicator of death over time. (*P < 0.05, 
**P < 0.01, ***P < 0.001)
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F I G U R E  3  Knockdown of 
Tyk2/TYK2 in JW23.3 murine MPNST 
and MPNST 724 cells affects expression 
of downstream targets. Western blot 
densitometry analysis on downstream 
targets of Tyk2/TYK2. Murine JW23.3 cell 
lines are depicted in blue/green, human 
MPNST 724 cell line are depicted in 
black/orange. (A and B) levels of TYK2 
normalized to GAPDH (C and D) levels 
of p‐STAT1 normalized to total STAT1. 
(E and F) levels of p‐STAT3 normalized 
to total STAT3. (G and H) levels of Bcl‐2 
normalized to GAPDH (I and J) levels 
of Cleaved Caspase-3 normalized to 
Caspase 3 levels. (*P < 0.05, **P < 0.01, 
***P < 0.001) All experiments were done 
in triplicate. Representative blots are shown
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fact, there was a very significant decrease in tumor burden, 
suggesting that there may be other cell death mechanisms 
at play in addition to apoptotic cell death. Nonetheless, 
the mice injected with Tyk2‐deficient cells exhibited less 
weight loss and had an increased overall survival, further 
supporting targeting this pathway in MPNSTs. Future stud-
ies will be aimed at better understanding the mechanisms 
at play in vivo. As we move forward with evaluating this 
pathway as a viable therapeutic target, another important 
aspect of TYK2 signaling that cannot be ignored is that 
TYK2 does not act alone, but is rather in a receptor com-
plex in which either JAK1 or JAK2 is also involved. Thus, 
drug development strategies will benefit from understand-
ing which of the other JAK family members are important 
in MPNST biology. Future work will be aimed at identify-
ing the most effective inhibitor from in vitro studies and 
then evaluating the in vivo efficacy of the most promising 
TYK2 inhibitors to test as a single agent and in combina-
tion therapies.
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F I G U R E  4  shRNA‐mediated 
knockdown of Tyk2 in JW23.3 murine 
MPNST cells leads to decreased tumor 
growth in vivo. (A) Dissected tumors from 
subcutaneous injection of shTyk2‐infected 
JW23.3 cell lines and control shLacZ. (B) 
Quantification of subcutaneous tumor 
volume over time. (C) Quantification of the 
number of Cleaved Caspase-3 positive cells 
from immunohistochemistry of harvested 
subcutaneous tumors of shTyk2‐infected 
JW23.3 cell lines and control shLacZ. 
(D) Representative images of Cleaved 
Caspase-3 immunohistochemistry. (E) 
Tumor burden over time as measured 
by photon flux in mice injected 
intraventricularly. (F) Representative 
images of mice following intraventricular 
injection. (n = 5 for all groups; *P < 0.05, 
**P < 0.01, ***P < 0.001)
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